Kolonkarzinom: Aktueller Stand der multimodalen Therapie

Zusammenfassung

Im UICC-I-Stadium kann bei T1-Karzinomen mit einem geringen Risikoprofil für eine Lymphknotenmetastasierung bei selektionierten Patienten auf eine chirurgisch onkologische Resektion verzichtet werden, wenn der Befund komplett endoskopisch entfernt wurde. Im Stadium UICC II ist eine routinemäßige adjuvante CT nicht indiziert, lediglich bei Patienten mit einem Hochrisiko­pro­fil (T4-Tumor, weniger als 12 histopathologisch untersuchte Lymphknoten, Notfall-OP, intraoperative Tumorperforation) sollte auch in diesem Tumorstadium eine adjuvante CT mit 5-FU / FS durchgeführt werden. Standardtherapie im Sta­dium UICC III ist eine adjuvante CT nach dem FOLFOX4-Protokoll. Irinotecan und Antikörpertherapien erbringen in diesem Tumorstadium keine zusätzliche Verbesserung der Überlebensdaten. Aufgrund möglicher Nebenwirkungen der CT sollten Patienten, die älter als 70 Jahre sind, bevorzugt ein infusionales 5-FU / FS-Protokoll oder oral Capecitabine erhalten. Im Stadium IV mit resektablen Lebermetastasen steht die chirurgische Entfernung des Primärtumors und der Metastasen im Vordergrund. Der Vorteil einer neoadjuvanten, perioperativen oder adjuvanten CT ist bei resek­tablen Lebermetastasen augenblicklich nicht hinreichend belegt. Hierüber sollte individuell in ­einem Tumorboard entschieden werden. Bei primär nicht resektablen Lebermetastasen ist die Durchführung einer neoadjuvanten Chemotherapie indiziert. Hierzu bietet sich ein FOLFOX-Protokoll, kombiniert z. B. mit dem monoklonalen Antikörper Cetuximab, an. Ziel ist in dieser Situation die Verkleinerung der Metastasen und anschließende Resektion der Metastasen im Gesunden (R0). Patienten mit einer Mikrosatelliteninstabi­lität im Stadium UICC II haben eine vorteihafte Prognose und profitieren nicht von einer adjuvanten CT mit 5-FU / Folinsäure. Sollte bei diesen Patienten dennoch eine CT erwogen werden, empfiehlt sich die Bestimmung der MSI im Tumorgewebe und bei ­positivem Befund eine Kombinations-CT, z. B. mit FOLFOX. Die weitere Bedeutung der MSI für andere Tumorstadien ist augenblicklich nicht hinreichend evaluiert. Vor einer Therapie mit dem monoklonalen Antikörper Cetuximab oder Panitumumab muss der KRAS-Status bestimmt werden, da eine solche Therapie nur bei einem KRAS-Wildtyp im Tumorgewebe wirksam ist. 

Abstract

In UICC stage I a selected group of patients with T1 tumours and a low risk profile regarding simultaneous lymph node metastases can be treated by endoscopic resection alone, if the tumour is thereby completely removed. In UICC stage II an adjuvant chemotherapy (CT) should not be routinely performed. However, in high risk UICC stage II patients (T4 tumour, less than 12 examined lymph nodes, emergency surgery, intraoperative tumour perforation), an adjuvant CT with infusional 5-FU / FA should be recommended. The state of the art in UICC stage III is an adjuvant CT with FOLFOX. In this tumour stage no beneficial effect of CT involving irinotecan or monoclonal antibodies has been documented. Due to CT-induced side effects an infusional 5-FU / FA protocol or oral capecitabine should be given in patients older than 70 years. In stage UICC IV with resectable liver metastases, surgical resection of the primary tumour and the metastases should be implemented. Since no conclusive data are currently available regarding the beneficial effect of neoadjuvant, perioperative or adjuvant CT in this setting, the therapeutic strategy should be individually discussed between surgeons and oncologists (tumour board). In cases of non-resectable liver metastases a neoadjuvant CT should be performed, preferentially with a FOLFOX protocol in combination with targeted therapies, i. e., the monoclonal antibody cetuximab, aimed at tumour regression with radical metastasectomy as the secondary intent (R0). Patients with UICC stage II colon cancer and microsatellite instability (MSI) apparently experience a better prognosis but do not profit from an adjuvant CT with 5-FU / FA alone. If a CT is under consideration for these patients, the MSI status should be determined on tumour tissue. In cases of a positive result a combination CT, i. e., with FOLFOX, should be given. The relevance of the MSI status in other tumour stages is as yet unknown. Before targeted therapies, i. e., cetuximab or panitumumab, are initiated, the KRAS status needs to be determined, since therapies with antibodies against the epithelial growth factor receptor (EGFR) are only effective in tumours bearing the KRAS wild-type. 

Schlüsselwörter

Kolonkarzinom - multimodale Therapie - Therapie

Key words

colon cancer - multimodal therapy - therapy

Literatur

• 1 Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Kebsregister in Deutschland e. V. (Hrsg). Krebs in Deutschland 2005/2006. Häufigkeiten und Trends. 7. Ausgabe Berlin: Westkreuz-Druckerei; 2010: 36-39 ISBN 978-3-89606-207-9
• 2 Link K H, Mörschel M, Sagban T A et al. Chirurgie und multimodale Therapie des Kolonkarzinoms: Evidensbasis?.  Chir Gastroenterol. 2004;  20 39-54
• 3 Link K H, Kornmann M, Staib L et al. Increase of survival benefit in advanced resectable colon cancer by extent of adjuvant treatment: results of a randomized trial comparing modulation of 5-FU + levamisole with folinic acid or with interferon-alpha.  Ann Surg. 2005;  242 178-187
• 4 Andre T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil, and leucoverin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.  J Clin Oncol. 2009;  27 3109-3116
• 5 Bokemeyer C, Bondarenko I, Hartmann J T et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience.  J Clin Oncol. 2008;  26 78-178
• 6 Van Cutsem E, Lang I, D’haens G et al. KRAS status and efficacy in the first line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience.  J Clin Oncol. 2008;  26 suppl 5
• 7 Kornmann M, Schwabe W, Sander S et al. Thymidylate Synthase and ­Dihydropyrimidine Dehydrogenase mRNA Expression Levels: Predictors for Survival in Colorectal Cancer Patients Receiving Adjuvant 5-Flurouracil.  Clin Canc Res. 2003;  9 4116-4124
• 8 Popat S, Hubner R, Houlston R S. Systemic review of microsatellite instability and colorectal cancer prognosis.  J Clin Oncol. 2005;  23 609-618
• 9 Ribic C M, Sargent D J, Moore M J et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.  N Engl J Med. 2003;  349 247-257
• 10 Feifel G, Hildebrandt U. Neue Entwicklungen in der operativen Therapie des Kolonkarzinoms.  Onkologe. 1999;  1 24-29
• 11 Weber T, Link K H. Radikale Chirurgie bei primär metastasierten kolo­rektalen Karzinomen.  Chir Gastroenterol. 2007;  23 360-366
• 12 Fleshman J, Sargent D J, Green E et al. Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study group trial.  Ann Surg. 2007;  246 655-662
• 13 Buunen M, Veldkamp R, Hop W C et al. Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomized clinical trial.  Lancet Oncol. 2009;  10 44-52
• 14 Lacy A M, Delgado S, Castellas A et al. The long term results of a randomized clinical trial of laparoscopy-assisted versus open surgery for colon cancer.  Ann Surg. 2008;  248 1-7
• 15 Weber T, Link K H. Submukosakarzinome des Gastrointestinaltraktes – Kolon: pro Chirurgie.  Viszeralmedizin. 2009;  25 40-45
• 16 Link K H, Sagbahn T A, Mörschel M et al. Colon cancer: survival after curative surgery.  Langenbecks Arch Surg. 2005;  390 83-93
• 17 Chok K SH, Law W L. Prognostic factors affecting survival and recurrence of patients with pT1 and pT2 colorectal cancer.  World J Surg. 2007;  31 1485
• 18 Greene F L, Stewart A K, Norton H J. A new TNM staging strategy for node positive (Stage III) colon cancer: an analysis of 50 042 patients.  Ann Surg. 2002;  236 416-421
• 19 Deinlein P, Reulbach U, Stolte M et al. Risikofaktoren der lymphogenen Metastasierung von kolorektalen pT1 Karzinomen.  Pathologe. 2003;  24 387-393
• 20 Hassan C, Zullo A, Risio M et al. Histologic risk factors and clinical outcome in colorectal malignant polyp: a pooled analysis.  Dis Colon Rectum. 2005;  48 1588-1596
• 21 Schmiegel W, Reinacher-Schick A, Arnold D et al. S3-Leitline „Kolorektales Karzinom“ – Aktualisierung 2008.  Z Gastroenterol. 2008;  46 799-840
• 22 Kikuchi R, Takano M, Takagi K et al. Management of early invasive colorectal cancer. Risk of recurrence and clinical guidelines.  Dis Colon Rectum. 1995;  38 1286-1295
• 23 Yasuda K, Inomata M, Shiromizu A et al. Risk factors for occult lymph node metastasis of colorectal cancer invading the submucosa and indications for endoscopic mucosal resection.  Dis Colon Rectum. 2007;  50 1370-1376
• 24 Yamamoto S, Watanabe M, Hasegawa H et al. The risk of lymph node metastasis in T1 colorectal carcinoma.  Hepatogastroenterology. 2004;  51 998-1000
• 25 Suzuki T, Sadahiro S, Mukoyama S et al. Risk of lymph node and distant metastases in patients with early invasive colorectal cancer classified as Haggitt’s level 4 invasion: image analysis of submucosal layer invasion.  Dis Colon Rectum. 2003;  46 203-208
• 26 Gill S, Loprinzi C L, Sargent D J et al. Pooled analysis of fluorouracil based adjuvant therapy for stage II and III colon cancer: who benefits and by how much ?.  J Clin Oncol. 2004;  22 1797-1806
• 27 Gray R, Barnwell J, McConkey C et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomized study.  Lancet. 2007;  370 2020-2029
• 28 Morris M, Platell C, de Boer M et al. Population based study of prognostic factors in stage II colonic cancer.  Br J Surg. 2006;  93 866-871
• 29 Jestin P, Nilsson J, Heurgren M et al. Emergency surgery for colonic cancer in a defined population.  Br J Surg. 2005;  92 94-100
• 30 McArdle C S, McMillan D C, Hole D J. The impact of blood loss, obstruction and perforation on survival in patients undergoing curative resection for colon cancer.  Br J Surg. 2006;  93 483-488
• 31 George S, Primrose J, Talbot R et al. Will Rogers revisted: prospective observational study of survival of 3592 patients with colorectal cancer according to number of nodes examined by pathologists.  Br J Cancer. 2006;  95 841-847
• 32 Chen S l, Bilchik A J. More extensive nodal dissection improves survival for stages I to III of colon cancer: a population-based study.  Ann Surg. 2006;  244 602-610
• 33 O’Connell M J, Mailliard J A, Kahn M J et al. Controlled trial of fluorouracil and low-dose leucovorin given 6 months as postoperative adjuvant therapy for colon cancer.  J Clin Oncol. 1997;  15 246-250
• 34 Teixeira L, Hickish T, Tournigand C et al. Efficacy of FOLFOX4 as adjuvant therapy in stage II colon cancer: A new analysis of the mosaic trial according to risk factors.  J Clin Oncol. 2010;  28 3524
• 35 Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer.  New Engl J Med. 2004;  350 2343-2351
• 36 Kuebler J P, Wieand H S, O’Connell M J et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.  J Clin Oncol. 2007;  25 2198-2204
• 37 Twelves C, Wong A, Nowacki M P et al. Capecitabine as adjuvant treatment for stage III colon cancer.  N Engl J Med. 2005;  352 2696-2704
• 38 Haller D, Tabernero J, Maroun J et al. First efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU / LV for stage III colon cancer (NO16968/XELOXA study).  Eur J Cancer. 2009;  4
• 39 Saltz L B, Niedzwiecki D, Hollis D et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.  J Clin Oncol. 2007;  25 3456-3461
• 40 Van Cutsem E, Labianca R, Bodoky G et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.  J Clin Oncol. 2009;  27 3117-3125
• 41 Wolmark N, Yothers G, O’Connell M J et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP protocol C-08.  J Clin Oncol. 2009;  18
• 42 Alberts S R, Sargent D J, Smyrk T C et al. Adjuvant mFOLFOX6 with or without cetuximab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): results from NCCTG Intergroup phase III trial N0147.  J Clin Oncol. 2010;  28 18
• 43 Chau I, Cunningham D. Adjuvant therapy in colon cancer: what, when and how?.  Ann Oncol. 2006;  1 1347-1359
• 44 Jackson McCleary A J, Meyerhardt J, Green E et al. Impact of older age on the efficacy of newer adjuvant therapies in > 12 500 patients with stage II / III colon cancer: Findings from the ACCENT Database.  J Clin Oncol. 2009;  27 15
• 45 Sargent D J, Goldberg R M, Jacobson S D et al. A pooled analysis of ad­juvant chemotherapy for resected colon cancer in elderly patients.  N Engl J Med. 2001;  345 1091-1097
• 46 Schmiegel W, Pox C, Arnold D et al. Kolorektales Karzinom – Polypenmanagement, (neo)adjuvante Therapie, Therapie im metastasierten Stadium.  Dtsch Arztebl Int. 2009;  106 843-848
• 47 Link K H, Pillasch J, Formentini A et al. Downstaging by regional chemotherapy of non-resectable isolated colorectal liver metastases.  Eur J Surg Oncol. 1999;  25 381-388
• 48 Bismuth H, Adam R, Levi F et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy.  Ann Surg. 1996;  224 509-522
• 49 Simmonds P C, Primrose J N, Colquitt J L et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies.  Br J Cancer. 2006;  94 982-999
• 50 Nordlinger B, Sorbye H, Glemelius B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial.  Lancet. 2008;  371 1007-1016
• 51 Portier G, Dominique E, Bouche O et al. Multicenter randomized trial of adjuvant fluorouracil and folonic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.  J Clin Oncol. 2006;  24 4976-4982
• 52 Langer B, Bleiberg H, Labianca R et al. Fluorouracil (FU) plus I-leuco­vorin (I–LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC / NCIC CTG / GIVIO) randomized trial.  Proc Am Soc Clin Oncol. 2002;  21
• 53 Mitry E, Fields A, Bleiberg H et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials.  J Clin Oncol. 2008;  26 4906-4911
• 54 Ychou M, Hohenberger W, Thezenas S et al. Randomized phase III trial comparing infused 5-fluorouracil / folonic acid (LV5FU2) versus LV5FU2 + irinotecan (LV5FU2 + IRI) as adjuvant treatment after complete resection of liver metastases from colorectal cancer (LMCRC) (CPT-GMA-301).  J Clin Oncol. 2008;  26 181
• 55 Alberts S R, Horvath W L, Sternfeld W C et al. Oxaliplatin, fluorouracil and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group Phase II Study.  J Clin Oncol. 2005;  23 9243-9249
• 56 Pozzo C, Basso M, Cassano A et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients.  Ann Oncol. 2004;  15 933-939
• 57 Folprecht G, Gruenberger T, Bechstein W O et al. Tumor response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomized phase 2 trial.  Lancet Oncol. 2010;  11 38-47
• 58 Rubbia-Brandt L, Audard V, Sartoretti P et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.  Ann Oncol. 2004;  15 460-466
• 59 Pawlik T M, Olino K, Gleisner A L et al. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome.  J Gastrointest Surg. 2007;  11 860-868
• 60 Vauthey J N, Pawlik T M, Ribero D et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases.  J Clin Oncol. 2006;  24 2065-2072
• 61 Mehta N N, Ravikumar R, Coldham C A et al. Effect of preoperative chemotherapy on liver resection for colorectal liver metastases.  Eur J Surg Oncol. 2008;  34 782-786
• 62 Dietmaier W. Mikrosatelliteninstabilität.  Pathologe. 2010;  31 268-273
• 63 Koopman M, Kortman G A, Mekenkamp L et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer.  Br J Cancer. 2009;  100 266-273
• 64 Tejpar S, Bosman F, Delorenzi M et al. Micriosatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5-FU-LV and irinotecan (PETACC 3 – EORTC 40993 – SAKK 60 / 00 trial).  J Clin Oncol. 2009;  27 4001
• 65 Bertagnolli M M, Niedzwiecki D, Compton C C et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil and leucovorin in stage III colon cancer: Cancer and leukemia group B protocol 89803.  J Clin Oncol. 2009;  27 1814-1821
• 66 Kim S T, Lee J, Park S H et al. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.  Cancer Chemother Pharmacol. 2010;  66 659-667
• 67 Bekaii-Saab T. KRAS testing in metastatic colorectal cancer: Implications on the use of biologic agents.  Clin Colorectal Cancer. 2009;  8 135-140